

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 652 872 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
08.11.2000 Bulletin 2000/45

(21) Application number: 94917244.9

(22) Date of filing: 27.05.1994

(51) Int. Cl.⁷: C07D 401/12, A61K 31/44

(86) International application number:
PCT/SE94/00509

(87) International publication number:
WO 94/27988 (08.12.1994 Gazette 1994/27)

(54) OPTICALLY PURE MAGNESIUM -SALT OF PYRIDINYLMETHYL SULFINYL-1H-BENZIMIDAZOLE COMPOUND

OPTISCH REINES MAGNESIUM-SALZ EINES PYRIDINYLMETHYLSULFINYL-1H-BENZIMIDAZOLE-DERIVATS

SEL DE MAGNESIUM OPTIQUEMENT PUR DE COMPOSE DE PYRIDINYLMETHYLE SULFINYL-1H-BENZIMIDAZOLE

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE
Designated Extension States:
SI

(30) Priority: 28.05.1993 SE 9301830

(43) Date of publication of application:
17.05.1995 Bulletin 1995/20

(60) Divisional application:
00108480.5 / 1 020 461
00108479.7 / 1 020 460

(73) Proprietor: AstraZeneca AB
151 85 Södertälje (SE)

(72) Inventors:
• LINDBERG, Per, Lennart
S-431 51 Mölndal (SE)
• VON UNGE, Sverker
S-430 33 Fjärås (SE)

(56) References cited:
EP-A- 0 124 495 DE-A- 4 035 455

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Printed by Xerox (UK) Business Services
2.16.7 (MPS)CLB

EP 0 652 872 B1

BEST AVAILABLE COPY